Bria McKee
Family Health · Huntington, WVNPI 1679946206
Payments from drug & device makers
Across 363 payments — averaging $132.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$42K
- Abbott$1K
- Lilly USA, LLC$858
- Insulet Corporation$466
- Novartis$439
- Boehringer Ingelheim$363
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$39,70582%
- Travel & lodging$1,7944%
- Food & beverage$6,62214%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 114 | $42,489 |
| Abbott | 70 | $1,457 |
| Lilly USA, LLC | 29 | $858 |
| Insulet Corporation | 16 | $466 |
| Novartis | 32 | $439 |
| Boehringer Ingelheim | 2 | $363 |
| AstraZeneca(2 entities) | 18 | $322 |
| Medtronic | 3 | $236 |
| AbbVie | 11 | $224 |
| Amgen | 9 | $126 |
| Bayer | 7 | $123 |
| Dexcom, Inc. | 6 | $102 |
| Shield Therapeutics Inc | 5 | $93 |
| Esperion Therapeutics, Inc. | 6 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $75 |
| Halozyme Inc | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Radius Health, Inc. | 1 | $50 |
| Argenx US, Inc. | 2 | $43 |
| Antares Pharma, Inc. | 1 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Globus Medical | 1 | $36 |
| Cequr Corporation | 1 | $34 |
| Smith+Nephew | 2 | $33 |
| Lundbeck LLC | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$34,551
- Ozempic$5,680
- JARDIANCE$700
- FREESTYLE LIBRE 3$367
- MINIMED 770G$225
- FreeStyle Libre$218
- Omnipod$121
How this compares
Too few family health providers in West Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 849 | $1,219,164 |
| OzempicSemaglutide | 284 | $403,160 |
| JardianceEmpagliflozin | 309 | $359,280 |
| FarxigaDapagliflozin Propanediol | 213 | $213,741 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 142 | $182,870 |
| Tresiba Flextouch U-100Insulin Degludec | 196 | $171,709 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 77 | $140,259 |
| Tresiba Flextouch U-200Insulin Degludec | 79 | $135,769 |
| TrulicityDulaglutide | 70 | $133,002 |
| RybelsusSemaglutide | 50 | $81,273 |
| TradjentaLinagliptin | 81 | $74,737 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $68,761 |
| Novolog FlexpenInsulin Aspart | 192 | $61,373 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $53,612 |
| JanuviaSitagliptin Phosphate | 46 | $52,728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $858 | $1,384,212968 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $42,489 | $549,898426 claims |
| Boehringer IngelheimJardiance, Tradjenta | $363 | $434,017390 claims |
| AstraZenecaFarxiga | $322 | $213,741213 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $23 | $73,97260 claims |
| Johnson & JohnsonInvokana | $12 | $21,79517 claims |
| AbbVieSynthroid | $224 | $6,84568 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in West Virginiaon file to place this against a meaningful peer group, so we don't.
Other family health in Huntington
- Charlotte ReedPoint Pleasant$178
- Cheryl GreenCowen$94
- Haley MarchiMartinsburg$24
- Lisa McCloudWilliamson$7
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.